Ebos's Near-Term Earnings Outlook Dims -- Market Talk

Dow Jones09-09

2223 GMT - Pharmacy group Ebos's annual earnings guidance of A$615 million-A$635 million was weaker than expected. It's also entering FY26 with a new CEO. "This coupled with a step-up in depreciation and amortization (A$140 million-A$150 million) and net interest (A$110 million-A$120 million) drives a reset our near-term forecasts," analyst Tom Godfrey says. Ord Minnett cuts its Ebitda forecast by 7%, to A$627 million, with a larger 18% reduction in net profit, to A$267 million. Its price target falls 13%, to A$33.00/share, as a result. Still, Ord Minnett retains an "accumulate" call on Ebos. "Looking ahead, we continue to view Ebos as a quality operator, with consistent growth strategies and a strong capital allocation track record," it says. "This underpins improving EPS growth medium term." (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

September 08, 2025 18:23 ET (22:23 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2566300436?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 06:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566300436","market":"fut","top_or_hot":-1,"title":"Ebos's Near-Term Earnings Outlook Dims -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  2223 GMT - Pharmacy group Ebos's annual earnings guidance of A$615 million-A$635 million was weaker than expected. It's also entering FY26 with a new CEO. \"This coupled with a step-up in depreciation and amortization (A$140 million-A$150 million) and net interest (A$110 million-A$120 million) drives a reset our near-term forecasts,\" analyst Tom Godfrey says. Ord Minnett cuts its Ebitda forecast by 7%, to A$627 million, with a larger 18% reduction in net profit, to A$267 million. Its price target falls 13%, to A$33.00/share, as a result. Still, Ord Minnett retains an \"accumulate\" call on Ebos. \"Looking ahead, we continue to view Ebos as a quality operator, with consistent growth strategies and a strong capital allocation track record,\" it says. \"This underpins improving EPS growth medium term.\" (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 08, 2025 18:23 ET (22:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ebos's Near-Term Earnings Outlook Dims -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEbos's Near-Term Earnings Outlook Dims -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-09 06:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  2223 GMT - Pharmacy group Ebos's annual earnings guidance of A$615 million-A$635 million was weaker than expected. It's also entering FY26 with a new CEO. \"This coupled with a step-up in depreciation and amortization (A$140 million-A$150 million) and net interest (A$110 million-A$120 million) drives a reset our near-term forecasts,\" analyst Tom Godfrey says. Ord Minnett cuts its Ebitda forecast by 7%, to A$627 million, with a larger 18% reduction in net profit, to A$267 million. Its price target falls 13%, to A$33.00/share, as a result. Still, Ord Minnett retains an \"accumulate\" call on Ebos. \"Looking ahead, we continue to view Ebos as a quality operator, with consistent growth strategies and a strong capital allocation track record,\" it says. \"This underpins improving EPS growth medium term.\" (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 08, 2025 18:23 ET (22:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EBO.NZ","symbol_name":"Ebos Group Limited Ordinary Shares","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2566300436","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566300436","pubTimestamp":1757370180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2223 GMT - Pharmacy group Ebos's annual earnings guidance of A$615 million-A$635 million was weaker than expected. It's also entering FY26 with a new CEO. \"This coupled with a step-up in depreciation and amortization  and net interest  drives a reset our near-term forecasts,\" analyst Tom Godfrey says. Ord Minnett cuts its Ebitda forecast by 7%, to A$627 million, with a larger 18% reduction in net profit, to A$267 million. Its price target falls 13%, to A$33.00/share, as a result. Still, Ord Minnett retains an \"accumulate\" call on Ebos. \"Looking ahead, we continue to view Ebos as a quality operator, with consistent growth strategies and a strong capital allocation track record,\" it says. \"This underpins improving EPS growth medium term.\" ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EBO.NZ":"Ebos Group Limited Ordinary Shares","EBO.AU":"EBOS GROUP LIMITED"},"translate_title":"Ebos近期盈利前景黯淡——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBO.NZ":0.9,"EBO.AU":0.9},"content_text":"2223 GMT - Pharmacy group Ebos's annual earnings guidance of A$615 million-A$635 million was weaker than expected. It's also entering FY26 with a new CEO. \"This coupled with a step-up in depreciation and amortization (A$140 million-A$150 million) and net interest (A$110 million-A$120 million) drives a reset our near-term forecasts,\" analyst Tom Godfrey says. Ord Minnett cuts its Ebitda forecast by 7%, to A$627 million, with a larger 18% reduction in net profit, to A$267 million. Its price target falls 13%, to A$33.00/share, as a result. Still, Ord Minnett retains an \"accumulate\" call on Ebos. \"Looking ahead, we continue to view Ebos as a quality operator, with consistent growth strategies and a strong capital allocation track record,\" it says. \"This underpins improving EPS growth medium term.\" (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 08, 2025 18:23 ET (22:23 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566300436","isCrawlerRequest":true}